Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$86.06 USD
+1.04 (1.22%)
Updated May 17, 2024 04:00 PM ET
After-Market: $85.92 -0.14 (-0.16%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth C Momentum F VGM
Brokerage Reports
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 501 - 520 ( 714 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Kyprolis sNDA Approved and Label Expands; Previewing 2Q15 Revenue
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
CHMP Recommends Promacta for SAA; Nearing Kyprolis'' sNDA PDUFA for MM
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Promacta Approved for Pediatric cITP, the First Under Novartis
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Teeing Up Next Partnering Event; ''6972 Shines at ADA
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
CVR Cash In; Tweaking Model and Upping Target to $135
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
"Low Hanging Fruit" Promacta Data for Next Potential Growth Phase
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
SAGE Going Pivotal Off of Positive Phase I/II; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
1Q15 Results, Pipeline Expands and Partners Cranking; Target to $127
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J